IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer

NCT05124795 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

18

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of Efficacy

Conditions

Metastatic Castration Resistant Prostate Cancer

Interventions

DRUG: IMU-935

Sponsor

Immunic AG